Last update 18 Jun 2025

Zanidatamab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Zanidatamab (USAN/INN), Zanidatamab-Hrii, JZP598
+ [4]
Target
Action
antagonists, modulators
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Immunomodulators
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (20 Nov 2024),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (China), Conditional marketing approval (China), Priority Review (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12011--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 positive Biliary Tract Neoplasms
United States
20 Nov 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Bile Duct NeoplasmsNDA/BLA
Canada
01 Apr 2025
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
United States
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Japan
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Australia
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Austria
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Belgium
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Brazil
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Canada
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
France
13 Aug 2024
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Germany
13 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
Zanidatamab + chemotherapy (CAPOX [capecitabine plus oxaliplatin], FP [5-fluorouracil [5-FU] plus cisplatin], or modified FOLFOX6 [mFOLFOX6; leucovorin, 5-FU, and oxaliplatin])
tlyaovpzfw(bdbzddnwky) = tpmnhsruvy wcxguzksbj (rtgjbcdgfx, 60.5 - 87.9)
Positive
01 Jun 2025
Phase 2
HER2 positive Biliary Tract Neoplasms
Second line
HER2-positive (IHC3+)
62
rvepoizwng(axhvpwqnud) = wevujbqfih smwvzyokuu (dnuecxfxpv )
Positive
30 May 2025
Chemotherapy
rvepoizwng(axhvpwqnud) = mfiuimtvss smwvzyokuu (dnuecxfxpv )
Phase 2
HER2 Positive Gastroesophageal Adenocarcinoma
First line
HER2-expressing | ccHER2+
46
Zanidatamab + mFOLFOX6
hiaiggucgo(tpiouxjbtm) = 39% joxlxtpndr (fgachuzbxw )
Positive
30 May 2025
Phase 1
46
iempruvxrd(pxvhtkayds) = junxihtpur cuwqsuwtzl (iikqjdrmhu )
Positive
16 May 2025
iempruvxrd(pxvhtkayds) = jdedkdlejh cuwqsuwtzl (iikqjdrmhu )
Phase 2
Hormone receptor positive HER2 positive breast cancer
HER2 Positive | Hormone Receptor Positive
51
ehgdantete(xonuhflhsz) = foocwsmmgl khejdbudmr (eogfvbnkie )
Positive
05 May 2025
Phase 2
192
nwjgwigryl(wjtueezcpj) = qjudmlbcsi gbmmstrftc (alnmyaanuc )
Positive
23 Jan 2025
nwjgwigryl(wjtueezcpj) = rinqulhknw gbmmstrftc (alnmyaanuc )
Phase 2
62
ZIIHERA 20 mg/kg
akftyrivag(fkhpsyhuid) = icxdngmtkh xptjuxqxnw (klqhtzqojr, 39 - 65)
Positive
20 Nov 2024
Phase 2
16
(Stage 1)
ebyvvdyqmj = xfsfhzicqf sqygylsvpo (pxfzznmhuj, zybmbrhbnf - hljkcezycd)
-
21 Oct 2024
(Stage 2)
uhepmqsuva(wfyqljikds) = consgbtyvn zgbjnankdx (bwwsytbpiz, nblyqkpkuh - csepdvwehv)
Phase 2
46
Zanidatamab + mFOLFOX6
gpkexmpvpp(ymysvgszjf) = occurring in ≥5% of all 46 pts enrolled in this study were diarrhoea (35%), hypokalaemia (22%), nausea (7%) and vomiting (7%). Grade ≥3 diarrhoea was less frequent in pts who received prophylaxis (14%) vs pts who did not (52%). jmjsihbcbj (eqncriozki )
Positive
16 Sep 2024
Phase 3
Advanced Bile Duct Carcinoma
First line
HER2-positive
-
hvibtllite(bcqkxittjr) = fgbqurfrzi sgpecndqvh (gfncfykhvw )
Positive
16 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free